Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peripheral blood stem cell graft CD34+ selected
- Development stage
- Unknown
- Lead developer
- Miltenyi Biotec
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Peripheral blood stem cell graft CD34+ selected is a cell therapy product consisting of enriched CD34+ hematopoietic stem and progenitor cells (HSPCs) harvested from mobilized peripheral blood. The selection process, typically performed using immunomagnetic devices like the CliniMACS system (Miltenyi Biotec), aims to provide a purified population of stem cells for hematopoietic reconstitution while depleting T cells to reduce the risk of graft-versus-host disease (GvHD) in allogeneic transplantation or removing malignant cells in autologous settings. This approach is utilized in the treatment of various hematologic malignancies, including acute leukemia, myelodysplastic syndrome, and multiple myeloma, as well as genetic blood disorders like sickle cell disease and thalassemia.
- Other names
- CD34-selected peripheral blood stem cellsCD-34-selected peripheral blood stem cellsCD 34-selected peripheral blood stem cellsCD34+ selected PBSCCD34+ enriched hematopoietic stem cellsCD34+ selected hematopoietic stem cell graft
Beyond the preview
Go deeper on peripheral blood stem cell graft CD34+ selected.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peripheral blood stem cell graft CD34+ selected.